Metraipolis › archive › dc_bbb0485db7c6

Amivantamab — Wikipedia (en)

Source
Wikipedia (en)
Original
https://en.wikipedia.org/wiki/Amivantamab
License (as archived)
CC-BY-SA-4.0
Archived
2026-11-08T22:41:43.991Z
SHA-256 of the archived text
1f62994a1292cd9323c31cc8b85cd56177b90888a92463aaa7c42dea37bff893
Stable URL of this page
https://metraipolis.com/documento/dc_bbb0485db7c6

How to cite

Amivantamab — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Amivantamab (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_bbb0485db7c6 (Metraipolis archive dc_bbb0485db7c6, sha256 1f62994a1292cd9323c31cc8b85cd56177b90888a92463aaa7c42dea37bff893)
BibTeX
@misc{dcbbb0485db7c6,
  title = {Amivantamab — Wikipedia (en)},
  howpublished = {Wikipedia (en)},
  url = {https://en.wikipedia.org/wiki/Amivantamab},
  note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_bbb0485db7c6; sha256 1f62994a1292cd9323c31cc8b85cd56177b90888a92463aaa7c42dea37bff893},
  year = {2026}
}

Archived text

Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Amivantamab. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Amivantamab, sold under the brand name Rybrevant, is a bispecific monoclonal antibody used to treat non-small cell lung cancer. Amivantamab is a bispecific epidermal growth factor (EGF) receptor-directed and MET receptor-directed antibody. It is the first treatment for adults with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The most common side effects include rash, infusion-related reactions, skin infections around the fingernails or toenails, muscle and joint pain, shortness of breath, nausea, fatigue, swelling in the lower legs or hands or face, sores in the mouth, cough, constipation, vomiting and changes in certain blood tests. Amivantamab was approved for medical use in the United States in May 2021, and in the European Union in December 2021. The US Food and Drug Administration considers it to be a first-in-class medication.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico).
Fonte: Wikipedia in inglese, voce «Amivantamab» — https://en.wikipedia.org/wiki/Amivantamab
Wikidata Q106957199: «medication» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q106957199
Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Amivantamab?action=history).
Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza.
Estratto dell'introduzione non modificato nel contenuto; revisione 1335942983, consultata il 2026-11-08T22:37:40.536Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: 15d8fa374f8a154c4a64880dd6b4e057127847258cd186f689b261b0725a5199